[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 31 of about 31
1. Varghese BT, Ramdas K, Sebastian P, Nair MK: Salvage chemotherapy and surgery for radio recurrent carcinoma glottis. Indian J Cancer; 2003 Jul-Sep;40(3):113-5
Hazardous Substances Data Bank. METHOTREXATE .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Salvage chemotherapy and surgery for radio recurrent carcinoma glottis.
  • Chemoradiotherapy is increasingly used in advanced laryngeal cancers.
  • They include histologically confirmed recurrent or residual disease or a symptomatic life threatening treatment sequelae.
  • Tumour recurrence or residivism can be managed by chemotherapy when radical surgery is either refused by the patient or if the general condition of the patient do not permit it.
  • However surgery becomes inevitable when life threatening treatment sequelae like absolute pharyngo-oesophageal stricture and aspiration sets in.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / radiotherapy. Laryngeal Neoplasms / radiotherapy. Neoplasm Recurrence, Local / drug therapy. Neoplasms, Radiation-Induced / drug therapy. Salvage Therapy
  • [MeSH-minor] Combined Modality Therapy. Esophageal Stenosis / etiology. Esophageal Stenosis / surgery. Humans. Male. Methotrexate / therapeutic use. Middle Aged. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14716115.001).
  • [ISSN] 0019-509X
  • [Journal-full-title] Indian journal of cancer
  • [ISO-abbreviation] Indian J Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Chemical-registry-number] 0 / Antineoplastic Agents; YL5FZ2Y5U1 / Methotrexate
  •  go-up   go-down


2. Ishihara S, Kubota S, Itoh J, Fujimoto Y, Nakashima T, Naganawa S: Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis. Head Neck Oncol; 2010 Jul 30;2:20

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiotherapy with or without chemotherapy for patients with T1-T2 glottic carcinoma: retrospective analysis.
  • BACKGROUND: To assess the results for local control (LC) and survival in patients with early-stage glottic cancer (GC) who were treated by radiotherapy (RT) with or without chemotherapy.
  • METHODS: Fifty-eight patients with T1-T2 squamous cell carcinoma of the glottis who were treated between 2001 and 2006 were analyzed retrospectively.
  • Of the 58 patients, eight developed recurrent disease at the primary site, and one had lymph node recurrences on the neck.
  • Only two patients died of laryngeal carcinoma, and one died of intercurrent disease.
  • CONCLUSIONS: The retrospective analysis showed a high rate of LC and larynx preservation in patients with T1-T2 GC by means of RT with or without chemotherapy.
  • There was, however, no statistical difference in LC rates for the two types of therapy.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / radiotherapy. Glottis / pathology. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Male. Middle Aged. Neoplasm Staging. Prognosis. Radiotherapy Dosage. Retrospective Studies. Survival Rate. Treatment Outcome

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Jan 1;46(1):21-6 [10656367.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2009 Mar 15;73(4):1104-9 [18950960.001]
  • [Cites] J Clin Oncol. 2001 Oct 15;19(20):4029-36 [11600604.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Jan 1;52(1):109-19 [11777628.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Feb 1;52(2):415-9 [11872287.001]
  • [Cites] Head Neck. 2002 Jul;24(7):637-42 [12112536.001]
  • [Cites] Int J Cancer. 2002 Aug 1;100(4):472-5 [12115532.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2002 Oct 1;54(2):471-8 [12243824.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2003 Feb 1;55(2):322-8 [12527044.001]
  • [Cites] Cancer. 2003 Aug 15;98(4):765-72 [12910521.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 1987 Mar;13(3):313-7 [3104243.001]
  • [Cites] Radiother Oncol. 1998 May;47(2):161-6 [9683364.001]
  • [Cites] Laryngoscope. 1998 Dec;108(12):1853-5 [9851503.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1378-86 [16095847.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2005 Dec 1;63(5):1387-94 [16115737.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Jan 1;64(1):77-82 [16169681.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2006 Mar 15;64(4):995-1001 [16406396.001]
  • [Cites] J Clin Oncol. 2006 Aug 1;24(22):3693-704 [16832122.001]
  • [Cites] Radiat Med. 2006 May;24(4):277-81 [16958401.001]
  • [Cites] Oncology. 2006;71(5-6):369-73 [17851262.001]
  • [Cites] Anticancer Res. 2007 Sep-Oct;27(5B):3497-500 [17972507.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2007 Dec 1;69(5):1389-94 [17869013.001]
  • [Cites] Auris Nasus Larynx. 2008 Jun;35(2):213-9 [17996416.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2000 Oct 1;48(3):723-35 [11020569.001]
  • (PMID = 20673360.001).
  • [ISSN] 1758-3284
  • [Journal-full-title] Head & neck oncology
  • [ISO-abbreviation] Head Neck Oncol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Other-IDs] NLM/ PMC2919535
  •  go-up   go-down


3. Holsinger FC, Lin HY, Bassot V, Laccourreye O: Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx. Cancer; 2009 Sep 1;115(17):3909-18
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Platin-based exclusive chemotherapy for selected patients with squamous cell carcinoma of the larynx and pharynx.
  • BACKGROUND: The current study was conducted to determine the long-term outcomes of patients with squamous cell carcinoma of the larynx and pharynx who were treated with platin-based exclusive chemotherapy (EC) after they achieved a complete clinical response (CCR) to induction chemotherapy.
  • METHODS: One hundred forty-two who achieved a CCR after platin-based induction chemotherapy were treated exclusively with additional chemotherapy, and 98.6% were followed for a minimum of 3 years or until death.
  • In multivariate analysis, primary tumor arising outside the glottic larynx (P = .0001) and a Charlson comorbidity index >1 (P = .0001) were associated with a statistically significant reduction in survival.
  • Salvage treatment resulted in an observed final local control rate of 93% that varied from 97.2% in patients who had glottic cancer to 88.7% in patients who had tumor originating from other sites (P = .097).
  • Combined chemotherapy with cisplatin and 5-fluorouracil (PF) allowed for the successful modulation of local therapy in 54.9% of patients.
  • For patients who developed recurrent disease after EC, this approach did not diminish survival and maintained function in the majority of patients.
  • Future work should be directed toward select markers of response to PF chemotherapy with which to identify those patients who are suited optimally for this approach.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Throat Cancer.
  • Hazardous Substances Data Bank. PLATINUM COMPOUNDS .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer. 1983 Apr 15;51(8):1353-5 [6681726.001]
  • [Cites] J Clin Oncol. 2003 Jan 15;21(2):327-33 [12525526.001]
  • [Cites] Head Neck Surg. 1983 Jul-Aug;5(6):500-7 [6885503.001]
  • [Cites] J Chronic Dis. 1987;40(5):373-83 [3558716.001]
  • [Cites] Cancer. 1987 Sep 15;60(6):1178-83 [3304610.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):265-72 [8158680.001]
  • [Cites] Br J Cancer. 1995 Jan;71(1):83-91 [7819055.001]
  • [Cites] Head Neck. 1995 Sep-Oct;17(5):377-81 [8522437.001]
  • [Cites] J Clin Oncol. 1996 Mar;14(3):838-47 [8622032.001]
  • [Cites] J Natl Cancer Inst. 1996 Jul 3;88(13):890-9 [8656441.001]
  • [Cites] J Clin Oncol. 1996 Aug;14(8):2331-6 [8708725.001]
  • [Cites] N Engl J Med. 2006 Feb 9;354(6):567-78 [16467544.001]
  • [Cites] Lancet Oncol. 2006 Jul;7(7):565-74 [16814208.001]
  • [Cites] N Engl J Med. 2006 Aug 10;355(6):570-80 [16899777.001]
  • [Cites] J Laryngol Otol. 2007 Feb;121(2):143-8 [17005065.001]
  • [Cites] N Engl J Med. 2008 Sep 11;359(11):1143-54 [18784104.001]
  • [Cites] Lancet. 2000 Mar 18;355(9208):949-55 [10768432.001]
  • [Cites] Laryngoscope. 2000 Jan;110(1):58-64 [10646717.001]
  • [Cites] Head Neck. 2004 Apr;26(4):365-72 [15054740.001]
  • [Cites] Br J Cancer. 2000 Dec;83(12):1594-8 [11189100.001]
  • [Cites] Cancer. 2001 Sep 15;92(6):1504-11 [11745228.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • (PMID = 19551883.001).
  • [ISSN] 0008-543X
  • [Journal-full-title] Cancer
  • [ISO-abbreviation] Cancer
  • [Language] ENG
  • [Grant] United States / NCI NIH HHS / CA / K12 CA88084; United States / NCI NIH HHS / CA / K12 CA088084-09; United States / NCI NIH HHS / CA / P30 CA016672; United States / NCI NIH HHS / CA / P50 CA097007; United States / NCI NIH HHS / CA / CA16672; United States / NCI NIH HHS / CA / K12 CA088084; United States / NCI NIH HHS / CA / P50 CA97007
  • [Publication-type] Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Platinum Compounds; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ NIHMS124415; NLM/ PMC3851301
  •  go-up   go-down


Advertisement
4. Hitt R, Jimeno A, Rodríguez-Pinilla M, Rodríguez-Peralto JL, Millán JM, López-Martín A, Brandariz A, Peña C, Cortés-Funes H: Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors. Br J Cancer; 2004 Dec 13;91(12):2005-11
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Phase II trial of cisplatin and capecitabine in patients with squamous cell carcinoma of the head and neck, and correlative study of angiogenic factors.
  • The combination of cisplatin and capecitabine was evaluated in patients with recurrent or unresectable squamous cell carcinoma of the head and neck (HNSCC), and outcome parameters were correlated with the expression of thymidine phosphorylase (TP), thymidilate syntetase (TS), vascular endothelial growth factor receptor (VEGFR) 1-3, and microvessel density (MVD).
  • Patients with recurrent or unresectable HNSCC were eligible if they had received prior neoadjuvant chemotherapy, concurrent chemo-radiotherapy, or no prior systemic therapy.
  • Cytoplasmic TP expression was more prevalent in patients with a laryngeal location vs other, and in patients with a recurrence vs primary disease.
  • Microvessel density count was higher in patients with recurrent vs primary disease.
  • The combination of cisplatin and capecitabine is effective in recurrent or unresectable HNSCC, and shows a manageable toxicity.
  • [MeSH-major] Angiogenesis Inducing Agents / metabolism. Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Cisplatin / therapeutic use. Deoxycytidine / analogs & derivatives. Deoxycytidine / therapeutic use. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Adult. Aged. Capecitabine. Fluorouracil / analogs & derivatives. Humans. Immunohistochemistry. Male. Middle Aged. Receptors, Vascular Endothelial Growth Factor / biosynthesis. Thymidine Phosphorylase / biosynthesis. Thymidylate Synthase / biosynthesis. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. CAPECITABINE .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Natl Cancer Inst. 2000 Feb 2;92(3):205-16 [10655437.001]
  • [Cites] J Biol Chem. 1964 Aug;239:2618-21 [14235544.001]
  • [Cites] Cancer Res. 2000 Nov 15;60(22):6298-302 [11103787.001]
  • [Cites] Pathol Int. 2001 Mar;51(3):158-64 [11328530.001]
  • [Cites] Cancer. 2001 Aug 1;92(3):556-68 [11505400.001]
  • [Cites] Anticancer Res. 2002 Mar-Apr;22(2B):1039-44 [12168898.001]
  • [Cites] Ann Surg. 2002 Dec;236(6):738-49; discussion 749 [12454512.001]
  • [Cites] Ann Oncol. 2003 Oct;14(10):1578-86 [14504061.001]
  • [Cites] N Engl J Med. 2003 Nov 27;349(22):2091-8 [14645636.001]
  • [Cites] Chem Pharm Bull (Tokyo). 1983 Jan;31(1):175-8 [6221809.001]
  • [Cites] J Clin Oncol. 1985 Aug;3(8):1105-8 [4040550.001]
  • [Cites] Acta Otolaryngol. 1987 May-Jun;103(5-6):519-28 [3303823.001]
  • [Cites] Biometrics. 1989 Jun;45(2):537-47 [2765637.001]
  • [Cites] J Clin Oncol. 1992 Feb;10(2):257-63 [1732427.001]
  • [Cites] J Clin Oncol. 1992 Aug;10(8):1245-51 [1634913.001]
  • [Cites] J Natl Cancer Inst. 1993 Jan 20;85(2):95-111 [8418313.001]
  • [Cites] J Natl Cancer Inst. 1994 Feb 16;86(4):250-2 [8158674.001]
  • [Cites] Ann Oncol. 1994 Jul;5(6):521-6 [7522527.001]
  • [Cites] Semin Surg Oncol. 1995 May-Jun;11(3):265-71 [7638514.001]
  • [Cites] Eur J Cancer. 1996 Jun;32A(7):1227-32 [8758258.001]
  • [Cites] J Clin Oncol. 1997 Jan;15(1):110-5 [8996131.001]
  • [Cites] J Clin Oncol. 1997 Oct;15(10):3223-9 [9336359.001]
  • [Cites] Cancer Res. 1998 Feb 15;58(4):685-90 [9485021.001]
  • [Cites] Biochem Pharmacol. 1998 Apr 1;55(7):1091-7 [9605432.001]
  • [Cites] Clin Cancer Res. 2000 Feb;6(2):381-9 [10690514.001]
  • (PMID = 15597103.001).
  • [ISSN] 0007-0920
  • [Journal-full-title] British journal of cancer
  • [ISO-abbreviation] Br. J. Cancer
  • [Language] eng
  • [Publication-type] Clinical Trial; Clinical Trial, Phase II; Comparative Study; Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Angiogenesis Inducing Agents; 0 / Antineoplastic Agents; 0W860991D6 / Deoxycytidine; 6804DJ8Z9U / Capecitabine; EC 2.1.1.45 / Thymidylate Synthase; EC 2.4.2.4 / Thymidine Phosphorylase; EC 2.7.10.1 / Receptors, Vascular Endothelial Growth Factor; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Other-IDs] NLM/ PMC2409797
  •  go-up   go-down


5. Chao KS, Low DA, Perez CA, Purdy JA: Intensity-modulated radiation therapy in head and neck cancers: The Mallinckrodt experience. Int J Cancer; 2000 Apr 20;90(2):92-103
ClinicalTrials.gov. clinical trials - ClinicalTrials.gov .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Intensity-modulated radiation therapy in head and neck cancers: The Mallinckrodt experience.
  • The purpose of the study was to investigate the feasibility and the optimization of tomotherapy-based intensity-modulated radiation therapy (IMRT) in patients with head and neck cancer.
  • From February 1997 to November 1997, 17 patients with squamous cell carcinoma of the head and neck were treated with IMRT.
  • Patients were immobilized with a noninvasive mask and treated using a serial tomotherapy device on a 6 MV linear accelerator.
  • Treatment planning was performed on a Peacock inverse planning system and prescription optimization was used to achieve the best plan for target coverage and parotid sparing.
  • The treatment planning system process has a dosimetric characteristic of delivering different doses to different target structures simultaneously in each daily treatment; therefore, the biological equivalent dose was implemented using the linear-quadratic model to adjust the total dose to the target volume receiving a daily dose of less than 1.9 Gy.
  • All eight patients with gross disease (six in the nasopharynx, two in the tonsil) and one patient with recurrent nasopharyngeal carcinoma received concurrent cisplatin chemotherapy.
  • All patients completed the prescribed treatment without unexpected interruption.
  • In the best-achievable plan of our studied cohort, only 27% +/- 8% of parotid gland volumes were treated to more than 30 Gy, while an average of 3.3% +/- 0.6% of the target volume received less than 95% of the prescribed dose.
  • The inverse planning system allowed us the freedom of weighting normal tissue-sparing and target coverage to select the best-achievable plan.
  • Further refining of delivery technology and the inverse planning system, gaining clinical experience to address target definition and dose inhomogeneity within the targets, and understanding the partial volume effect on normal tissue tolerance are needed for IMRT to excel in the treatment of head and neck cancer. Int. J.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Head and Neck Neoplasms / radiotherapy. Radiotherapy / methods
  • [MeSH-minor] Adult. Aged. Combined Modality Therapy. Humans. Laryngeal Neoplasms / radiotherapy. Magnetic Resonance Imaging. Middle Aged. Nasopharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / radiotherapy. Radiation Dosage. Tonsillar Neoplasms / radiotherapy. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Radiation Therapy.
  • COS Scholar Universe. author profiles.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Copyright 2000 Wiley-Liss, Inc.
  • (PMID = 10814959.001).
  • [ISSN] 0020-7136
  • [Journal-full-title] International journal of cancer
  • [ISO-abbreviation] Int. J. Cancer
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] UNITED STATES
  •  go-up   go-down


6. Lamont EB, Vokes EE: Chemotherapy in the management of squamous-cell carcinoma of the head and neck. Lancet Oncol; 2001 May;2(5):261-9
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemotherapy in the management of squamous-cell carcinoma of the head and neck.
  • Previously reserved for palliation, chemotherapy is now also a central component of several curative approaches to the management of patients with advanced-stage head and neck cancer.
  • Here we review the results of both induction chemotherapy and chemoradiotherapy trials in patients with curable disease, and chemotherapy trials in patients with recurrent and metastatic disease, and we highlight current areas of investigation.
  • Compared with traditional treatment modalities, chemotherapy given on induction schedules to patients with advanced laryngeal cancer allows greater organ preservation without compromise to survival; when given concomitantly with radiotherapy to patients with resectable or unresectable advanced disease, chemotherapy again improves survival.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Combined Modality Therapy. Drug Therapy, Combination. Humans. Nasopharyngeal Neoplasms / therapy. Neoplasm Recurrence, Local / drug therapy. Randomized Controlled Trials as Topic. Research. Survival Rate

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11905780.001).
  • [ISSN] 1470-2045
  • [Journal-full-title] The Lancet. Oncology
  • [ISO-abbreviation] Lancet Oncol.
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't; Review
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Antineoplastic Agents
  • [Number-of-references] 80
  •  go-up   go-down


7. Kohno N, Kitahara S: [Role of Chemotherapy in head and neck cancer]. Gan To Kagaku Ryoho; 2001 Apr;28(4):448-53
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Role of Chemotherapy in head and neck cancer].
  • For head and neck cancer, a recent meta-analysis of published randomized trial results showed that concurrent chemoradiotherapy, adjuvant chemotherapy and neoadjuvant chemotherapy may increase absolute survival by 12.1%, 6.5%, and 3.7%, respectively.
  • Initial response rates to first line chemotherapy are high, but this responsiveness does not appear to translate into a survival benefit.
  • Thus, chemotherapy can be indicated as the standard therapy for a very limited range of advanced head and neck cancers.
  • With the aim of prolonging survival, N stage advanced nasopharyngeal cancer is a good candidate for neoadjuvant chemotherapy.
  • Among a large number of randomized trials of neoadjuvant chemotherapy, organ function preservation studies showed the possibility of laryngeal preservation for locally resectable T2 and T3 laryngeal and hypopharyngeal cancer.
  • For N stage advanced pharyngeal cancer patients, adjuvant chemotherapy with applied after the standard therapy has a role in the treatment.
  • With palliative treatment in advanced and/or recurrent disease, there is less benefit from chemotherapy and indications for chemotherapy should be selected for individual patients.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Bleomycin / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Cisplatin / administration & dosage. Combined Modality Therapy. Dose-Response Relationship, Drug. Fluorouracil / administration & dosage. Humans. Palliative Care. Quality of Life. Survival Analysis

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • Hazardous Substances Data Bank. BLEOMYCIN .
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11329777.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 11056-06-7 / Bleomycin; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil
  • [Number-of-references] 11
  •  go-up   go-down


8. Knab BR, Salama JK, Solanki A, Stenson KM, Cohen EE, Witt ME, Haraf DJ, Vokes EE: Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma. Ann Oncol; 2008 Sep;19(9):1650-4
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Functional organ preservation with definitive chemoradiotherapy for T4 laryngeal squamous cell carcinoma.
  • BACKGROUND: Randomized trials established chemoradiotherapy as standard treatment for advanced laryngeal cancer.
  • The purpose of this study was to report T4 laryngeal cancer patient outcome, including those with LVT4 disease, treated with chemoradiotherapy.
  • PATIENTS AND METHODS: This study is a retrospective subset analysis of 32 patients with T4 laryngeal carcinoma including LVT4 tumors treated on three consecutive protocols investigating paclitaxel (Taxol), 5-fluorouracil, hydroxyurea, and 1.5-Gy twice daily (BID) radiotherapy (TFHX).
  • Four patients required laryngectomy for recurrent or persistent disease.
  • Induction chemotherapy improved 4-year LRC (90% versus 46%, P = 0.03) and DFS (84% versus 42%, P = 0.03).
  • CONCLUSIONS: Promising control and functional outcomes are achieved with TFHX for T4 laryngeal patients.
  • LVT4 disease had outcomes similar to patients with less advanced disease treated on Radiation Therapy Oncology Group 91-11.
  • Induction chemotherapy improved outcomes, warranting further investigation.

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • Hazardous Substances Data Bank. HYDROXYUREA .
  • Hazardous Substances Data Bank. TAXOL .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [CommentIn] Ann Oncol. 2010 Nov;21(11):2292-3 [20929963.001]
  • (PMID = 18467314.001).
  • [ISSN] 1569-8041
  • [Journal-full-title] Annals of oncology : official journal of the European Society for Medical Oncology
  • [ISO-abbreviation] Ann. Oncol.
  • [Language] ENG
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; U3P01618RT / Fluorouracil; X6Q56QN5QC / Hydroxyurea
  •  go-up   go-down


9. Farrag TY, Lin FR, Cummings CW, Koch WM, Flint PW, Califano JA, Broussard J, Bajaj G, Tufano RP: Neck management in patients undergoing postradiotherapy salvage laryngeal surgery for recurrent/persistent laryngeal cancer. Laryngoscope; 2006 Oct;116(10):1864-6
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Neck management in patients undergoing postradiotherapy salvage laryngeal surgery for recurrent/persistent laryngeal cancer.
  • OBJECTIVE: To determine a plan for the management of cervical lymph nodes in patients undergoing salvage laryngeal surgery (SLS) for recurrent/persistent laryngeal cancer after primary radiotherapy (RT).
  • METHODS: Charts of 51 consecutive patients who had salvage total or supracricoid laryngectomy with or without neck dissection for recurrent/persistent laryngeal squamous cell carcinoma after primary RT from 1988 to 2005 in our institution were reviewed.
  • No patients received concomitant or neo-adjuvant chemotherapy.
  • Reports of the final histopathologic examination for the excised laryngeal cancer and cervical lymph nodes were reviewed.
  • PreRT neck staging, preRT and preSLS staging of the primary tumor, along with laryngeal subsite involvement (supraglottis, glottis, subglottis) did not significantly correlate with the status of neck metastasis on final postSLS histopathology (P = .68, 0.78, 0.49, and 0.42, respectively).
  • In addition, all 17 patients who underwent SLS without neck dissection were staged N-0 both before RT as well as preSLS, and none developed neck disease in the postSLS follow-up period (median, 2.5 yr).
  • CONCLUSION: Management of the neck in patients undergoing salvage total or supracricoid laryngectomy for laryngeal cancer recurrence/persistence after primary RT should be based on the preSLS CT staging of the neck.
  • [MeSH-major] Laryngeal Neoplasms / surgery. Laryngectomy / methods. Neck Dissection. Neoplasm Recurrence, Local / surgery. Salvage Therapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / secondary. Carcinoma, Squamous Cell / surgery. Elective Surgical Procedures. Female. Follow-Up Studies. Humans. Lymphatic Metastasis / pathology. Male. Middle Aged. Neoplasm Staging. Neoplasm, Residual / radiotherapy. Neoplasm, Residual / surgery. Retrospective Studies. Tomography, X-Ray Computed

  • Genetic Alliance. consumer health - Laryngeal cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17003711.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


10. Labourey JL, Cupissol D, Calais G, Tourani JM, Kohser F, Borel C, Eymard JC, Germann N, Tubiana-Mathieu N: Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study. Am J Clin Oncol; 2007 Jun;30(3):278-82
Hazardous Substances Data Bank. DOCETAXEL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Docetaxel plus gemcitabine in recurrent and/or metastatic squamous cell carcinoma of the head and neck: a phase II multicenter study.
  • OBJECTIVES: This phase II study was conducted to assess the efficacy of docetaxel plus gemcitabine in locally recurrent and/or metastatic squamous cell carcinoma of the head and neck.
  • PATIENTS AND METHODS: Forty patients with pharynx or larynx cancer were included and treated with an intravenous infusion of docetaxel 75 mg/m2 on day 8 and gemcitabine 1000 mg/m2 day 1 and day 8 every 3 weeks for 6 cycles.
  • RESULTS: Among the 40 patients included, 17 had metastatic disease and 18 had received prior chemotherapy.
  • Three treatment-related deaths due to infection were reported.
  • CONCLUSION: The docetaxel and gemcitabine combination is an active treatment of recurrent or metastatic head and neck cancer.
  • However, this regimen is associated with a high hematologic toxicity.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / administration & dosage. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy
  • [MeSH-minor] Aged. Aged, 80 and over. Deoxycytidine / administration & dosage. Deoxycytidine / analogs & derivatives. Female. Humans. Laryngeal Neoplasms / drug therapy. Male. Middle Aged. Pharyngeal Neoplasms / drug therapy. Recurrence. Taxoids / administration & dosage. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17551305.001).
  • [ISSN] 1537-453X
  • [Journal-full-title] American journal of clinical oncology
  • [ISO-abbreviation] Am. J. Clin. Oncol.
  • [Language] eng
  • [Publication-type] Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Taxoids; 0W860991D6 / Deoxycytidine; 15H5577CQD / docetaxel; B76N6SBZ8R / gemcitabine
  •  go-up   go-down


11. El Bakkouri W, Racy E, Vereecke A, Gauthier A, Quillard J, Bobin S, Portier F: [Squamous cell carcinoma in a thyroglossal duct cyst]. Ann Otolaryngol Chir Cervicofac; 2004 Nov;121(5):303-5
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Squamous cell carcinoma in a thyroglossal duct cyst].
  • [Transliterated title] Carcinome épidermoïde sur kyste du tractus thyréogosse.
  • OBJECTIVE: To present a case of squamous cell carcinoma developed on a thyroglossal duct cyst in an adult patient.
  • Modalities of treatment and prevention are discussed.
  • Surgery was incomplete because of carotid artery and laryngeal involvement.
  • At two years follow-up, local progression was controlled by palliative chemotherapy.
  • DISCUSSION: For most authors, the risk of recurrent infections is the main reason for surgical resection of a thyroglossal duct cyst during childhood.
  • It is rather uncommon for carcinoma to develop on a thyroglossal duct cyst.
  • We discuss treatment in the event of malignant degeneration.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Thyroglossal Cyst / pathology. Thyroglossal Cyst / radiography
  • [MeSH-minor] Carotid Arteries / pathology. Combined Modality Therapy. Female. Humans. Larynx / pathology. Middle Aged. Neoplasm Invasiveness. Pain. Postoperative Care. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15711485.001).
  • [ISSN] 0003-438X
  • [Journal-full-title] Annales d'oto-laryngologie et de chirurgie cervico faciale : bulletin de la Société d'oto-laryngologie des hôpitaux de Paris
  • [ISO-abbreviation] Ann Otolaryngol Chir Cervicofac
  • [Language] fre
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] France
  •  go-up   go-down


12. Chen YF, Chen FJ, Yang AK, Zeng ZY, Song M, Li QL: [Clinical characteristics and multivariate analysis of prognostic factors in recurrent laryngeal carcinoma]. Ai Zheng; 2004 May;23(5):584-8

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical characteristics and multivariate analysis of prognostic factors in recurrent laryngeal carcinoma].
  • BACKGROUND & OBJECTIVE: The recurrence is an important factor affecting the prognosis of laryngeal carcinoma.
  • There are few reports on the clinical characteristics and the prognostic factors of recurrent laryngeal carcinoma.
  • The purpose of this study was to analyze the clinical features and prognostic factors of recurrent laryngeal carcinoma.
  • METHODS: The data of 80 patients with recurrent laryngeal carcinoma between 1990 and 1997 were retrospectively investigated.
  • The 3-year and 5-year overall survival rates for patients with recurrent laryngeal carcinoma were 50.6% and 34.6%, respectively.
  • The 5-year disease-specific survival rates for the patients treated with surgery, surgery + radiotherapy, and surgery +chemotherapy (30 cases) was 73%.
  • The recurrence of laryngeal carcinoma were developed within 1-156 months, the median time of recurrence was 11 months; there were 36 locoregional recurrence, 36 neck lymph node recurrence, 4 locoregional recurrence associated with neck lymph node recurrence, 1 locoregional recurrence associated with distant metastases, 3 neck lymph node recurrence associated with distant metastases.
  • Univariate analysis revealed that the factors impacting the prognosis were recurrent site, duration of recurrence gaps, treatment modality of recurrence, and age (P< 0.05).
  • The neck lymph node recurrence group, peristomal recurrence group, distant metastases group, radiotherapy and chemotherapy after recurrence group had a poorer prognosis than locoregional recurrence group, larynx recurrence group, without distant metastases group, and surgery group (P< 0.05).
  • Multivariate analysis showed that age > or =60 years old, duration of recurrence gap < 12 months, distant metastases and radiotherapy or chemotherapy modality after recurrence were independently associated with decreased survival rates (P< 0.05).
  • CONCLUSION: Surgery or surgery dominated multi-modality therapy was the principal treatment modality for recurrence laryngeal carcinoma.
  • Age > or =60 years old, duration of recurrence gap < 12 months, distant metastases and salvage therapy by radiotherapy and chemotherapy but not surgery were independent factors affecting the prognosis.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Laryngeal Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Adult. Age Factors. Aged. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Combined Modality Therapy. Female. Humans. Laryngectomy / methods. Lung Neoplasms / secondary. Lymphatic Metastasis. Male. Middle Aged. Multivariate Analysis. Neck Dissection. Prognosis. Proportional Hazards Models. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15142460.001).
  • [Journal-full-title] Ai zheng = Aizheng = Chinese journal of cancer
  • [ISO-abbreviation] Ai Zheng
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


13. Arnold DJ, Goodwin WJ, Weed DT, Civantos FJ: Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck. Semin Radiat Oncol; 2004 Apr;14(2):190-5
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of recurrent and advanced stage squamous cell carcinoma of the head and neck.
  • Despite advances in our ability to safely treat patients with recurrent cancer of the upper aerodigestive tract, outcomes for retreatment are generally poor and the first chance to cure these patients remains the best chance.
  • Thorough knowledge of the outlook and options for patients with recurrent disease is also of significance in choosing therapy for patients with newly diagnosed disease.
  • This is especially true for newly diagnosed patients making the choice between surgery and nonsurgical ("organ-sparing") options, who need to know the outlook for salvage surgery, should they recur after radiation with or without concomitant chemotherapy.
  • Salvage surgery is generally the best option for previously irradiated patients who are faced with resectable, recurrent disease.
  • Unfortunately, the results of surgical salvage are generally poor for patients with advanced stage recurrence and for those who recur after treatment of advanced disease.
  • The site of initial and recurrent disease is important.
  • Surgical salvage is most effective for patients with recurrent laryngeal cancer, least effective for recurrent cancer of the pharynx, and is intermediate for recurrence in the oral cavity.
  • Patients choosing nonsurgical treatment for newly diagnosed cancer of the pharynx cannot rely on salvage surgery in the event of recurrence.
  • Reirraditation for patients who have failed initial treatment that included radiation therapy has been used at a number of institutions with some success.
  • Experience using reirradiation with or without concomitant chemotherapy continues to evolve.
  • Palliative chemotherapy is an option for most patients, but response rates are generally poor and of short duration, after failure of initial treatment that includes radiation therapy.
  • The best approach for many patients and families who face advanced recurrent disease is honest but compassionate communication and supportive care with the help of a hospice organization.
  • [MeSH-major] Carcinoma, Squamous Cell / therapy. Head and Neck Neoplasms / therapy. Neoplasm Recurrence, Local / therapy
  • [MeSH-minor] Humans. Retreatment / methods. Salvage Therapy / methods

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15095264.001).
  • [ISSN] 1053-4296
  • [Journal-full-title] Seminars in radiation oncology
  • [ISO-abbreviation] Semin Radiat Oncol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Number-of-references] 15
  •  go-up   go-down


14. Miura K, Kum Y, Han G, Tsutsui Y: Radiation-induced laryngeal angiosarcoma after cervical tuberculosis and squamous cell carcinoma: case report and review of the literature. Pathol Int; 2003 Oct;53(10):710-5
Genetic Alliance. consumer health - Tuberculosis.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Radiation-induced laryngeal angiosarcoma after cervical tuberculosis and squamous cell carcinoma: case report and review of the literature.
  • Primary laryngeal angiosarcoma (LA) is quite rare with only 13 cases reported in English literature to date.
  • A case of LA after radiation therapy for tuberculosis and squamous cell carcinoma is reported.
  • A 70-year-old woman had a history of radiation therapy for left cervical tuberculosis at the age of 28.
  • At 60 years of age a squamous cell carcinoma of the larynx was found and chemotherapy and radiotherapy, consisting of a total dose of 68.4 Gy, were administered.
  • At the age of 68, recurrent squamous cell carcinoma was suspected from several biopsies, and a total laryngectomy with right thyroidectomy was performed.
  • No residual squamous cell carcinoma was found.
  • In the present case, it was suspected that irradiation to the larynx for cervical tuberculosis and squamous cell carcinoma induced angiosarcoma.
  • The patient was still alive despite multiple skin and soft tissue metastasis 3 years and 6 months after the radical operation.
  • Distinction of postirradiation angiosarcoma from pseudoangiosarcomatous carcinoma seems difficult but is important because irradiation is not effective and an initial radical surgery is the only effective treatment.
  • Although irradiation is a common treatment for laryngeal squamous cell carcinoma, this is only the second case of radiation-induced LA in English literature.
  • [MeSH-major] Carcinoma, Squamous Cell / etiology. Hemangiosarcoma / etiology. Laryngeal Neoplasms / etiology. Neoplasms, Multiple Primary / etiology. Neoplasms, Radiation-Induced / etiology. Tuberculosis, Lymph Node / radiotherapy
  • [MeSH-minor] Aged. Antineoplastic Agents / therapeutic use. Biomarkers, Tumor / analysis. Female. Humans. Immunohistochemistry. Laryngectomy. Neoplasm Recurrence, Local. Radiotherapy, Adjuvant. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14516323.001).
  • [ISSN] 1320-5463
  • [Journal-full-title] Pathology international
  • [ISO-abbreviation] Pathol. Int.
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Review
  • [Publication-country] Australia
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Biomarkers, Tumor
  • [Number-of-references] 30
  •  go-up   go-down


15. Baglam T, Sari M, Mine Yazici Z, Yuksel M, Uneri C: Chemiluminescence assay of reactive oxygen species in laryngeal cancer. J Laryngol Otol; 2010 Oct;124(10):1091-4
Genetic Alliance. consumer health - Laryngeal cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Chemiluminescence assay of reactive oxygen species in laryngeal cancer.
  • OBJECTIVE: This study aimed to evaluate the presence of reactive oxygen species in laryngeal cancer tissue, using a luminol-amplified chemiluminescence method.
  • MATERIALS AND METHODS: Fourteen patients with histopathologically diagnosed laryngeal squamous cell carcinoma were enrolled.
  • Patients with recurrent tumours or a history of prior chemotherapy or radiotherapy were excluded.
  • Tissue specimens were harvested both from the tumour itself and from the neighbouring, apparently normal mucosa (immediately after tumour removal).
  • Tissue specimens were washed with ice-cold saline solution and processed immediately, without storage.
  • RESULTS: The mean luminol-amplified chemiluminescence values for tumour and control tissue were 140.52 (standard error of the mean 40.21) and 121.36 (standard error of the mean 35.33) relative light units/mg tissue, respectively.
  • CONCLUSION: This study measured directly the levels of reactive oxygen species in samples of laryngeal cancer tissue and normal mucosa.
  • Higher levels of reactive oxygen species were found in laryngeal cancer tissue, suggesting a relationship between reactive oxygen species and laryngeal cancer.
  • [MeSH-major] Carcinoma, Squamous Cell / metabolism. Laryngeal Neoplasms / metabolism. Luminescent Measurements / methods. Oxidative Stress / physiology. Reactive Oxygen Species / metabolism
  • [MeSH-minor] Adult. Aged. Female. Humans. Laryngeal Mucosa / metabolism. Luminol / pharmacology. Male. Middle Aged. Neoplasm Staging

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20482946.001).
  • [ISSN] 1748-5460
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Reactive Oxygen Species; 5EXP385Q4F / Luminol
  •  go-up   go-down


16. Kovács AF, Eberlein K, Hülsmann T: Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus. Oral Maxillofac Surg; 2009 Jun;13(2):87-93
Hazardous Substances Data Bank. FLUOROURACIL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Organ preservation treatment using TPF-a pilot study in patients with advanced primary and recurrent cancer of the oral cavity and the maxillary sinus.
  • PURPOSE: Induction chemotherapy with Taxotere, cisplatin, and 5-fluororacil (TPF) was mainly used in hypopharyngeal and laryngeal cancer patients for larynx preservation.
  • PATIENTS AND METHODS: Between 2003 and 2008, 21 patients (18 male, three female; mean age 58 years; 15 patients Eastern Cooperative Oncology Group > or =1) suffering from advanced squamous cell cancers of the oral cavity (seven primaries, eight locoregional recurrences) and the maxillary sinus (six patients) were prospectively treated with three cycles of TPF (q3w) and were scheduled to undergo definitive chemoradiation.
  • Reasons for incomplete treatment were tumor progression, edema, seizure, bad general condition, sepsis, pneumonia (each once).
  • The infections led to two treatment-related deaths (9.5%).
  • Ten patients underwent a definitive chemoradiation or radiation (47.6%).
  • After a mean observation time of 17 months, nine patients are alive; one of them developed a local recurrence.
  • CONCLUSIONS: Chemotherapy with TPF is a highly effective treatment with considerable toxicity that needs special expertise which is best assured in a multidisciplinary setting.
  • Pretreated recurrent cancers demonstrated bad response.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Maxillary Sinus Neoplasms / drug therapy. Mouth Neoplasms / drug therapy. Neoplasm Recurrence, Local / drug therapy
  • [MeSH-minor] Aged. Antimetabolites, Antineoplastic / administration & dosage. Antimetabolites, Antineoplastic / adverse effects. Antineoplastic Agents / administration & dosage. Antineoplastic Agents / adverse effects. Cisplatin / administration & dosage. Cisplatin / adverse effects. Cisplatin / therapeutic use. Disease Progression. Feasibility Studies. Female. Fluorouracil / administration & dosage. Fluorouracil / adverse effects. Fluorouracil / therapeutic use. Follow-Up Studies. Humans. Leukopenia / chemically induced. Male. Middle Aged. Neoplasm Staging. Neutropenia / chemically induced. Opportunistic Infections / etiology. Pilot Projects. Prospective Studies. Radiotherapy, Adjuvant. Remission Induction. Stomatitis / chemically induced. Survival Rate. Taxoids / administration & dosage. Taxoids / adverse effects. Taxoids / therapeutic use

  • Genetic Alliance. consumer health - Oral cancer.
  • Genetic Alliance. consumer health - Sinus cancer.
  • MedlinePlus Health Information. consumer health - Oral Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Ann Oncol. 2009 May;20(5):921-7 [19179556.001]
  • [Cites] J Clin Oncol. 2006 Jun 20;24(18):2873-8 [16782926.001]
  • [Cites] Am J Clin Oncol. 2002 Oct;25(5):485-8 [12393990.001]
  • [Cites] Mund Kiefer Gesichtschir. 2006 May;10(3):168-77 [16604330.001]
  • [Cites] Oral Oncol. 2006 Aug;42(7):675-84 [16731029.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1695-704 [17960012.001]
  • [Cites] N Engl J Med. 2007 Oct 25;357(17):1705-15 [17960013.001]
  • [Cites] Am J Clin Oncol. 1982 Dec;5(6):649-55 [7165009.001]
  • [Cites] N Engl J Med. 1991 Jun 13;324(24):1685-90 [2034244.001]
  • [Cites] Otolaryngol Head Neck Surg. 2007 Jun;136(6):1003-9 [17547996.001]
  • [Cites] Int J Radiat Oncol Biol Phys. 2004 Jun 1;59(2):481-7 [15145166.001]
  • [Cites] Anticancer Res. 2006 Jan-Feb;26(1B):585-90 [16739325.001]
  • [Cites] Otolaryngol Clin North Am. 2005 Feb;38(1):75-85, viii [15649500.001]
  • [Cites] J Clin Oncol. 2005 Jan 1;23(1):88-95 [15625363.001]
  • (PMID = 19430823.001).
  • [ISSN] 1865-1550
  • [Journal-full-title] Oral and maxillofacial surgery
  • [ISO-abbreviation] Oral Maxillofac Surg
  • [Language] eng
  • [Publication-type] Clinical Trial; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Antineoplastic Agents; 0 / Taxoids; Q20Q21Q62J / Cisplatin; U3P01618RT / Fluorouracil; TPF protocol
  •  go-up   go-down


17. Shimane T, Mori T, Ono T, Monden T, Furuya A, Kobayashi S, Sanbe T, Suzaki H: [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL]. Gan To Kagaku Ryoho; 2009 Jul;36(7):1141-4
Genetic Alliance. consumer health - Carcinoma, Squamous Cell.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Two cases of head and neck squamous cell carcinoma in which S-1 administration resulted in long-term sustained QOL].
  • Palliative treatments are applied for older adult cases that are not indicated for either surgery or potential chemotherapy, as well as in cases with unresectable primary lesions, distant metastases, and serious complications among head and neck cancer cases.
  • There is no established treatment for such cases, and therefore treatment has to be selected on a case-by-case basis.
  • Two cases showing sustained QOL after long administration of S-1 are presented in this paper.
  • The second is a 70- year-old male patient who had recurrent cancer of the larynx (T1N0M0, stage I) after primary treatment.
  • Regulating the dosage and intervals of S-1 enabled the patients in both cases to survive with cancer as outpatients for 2 years and 2 months after the initial visit (1 year and 10 months from the start of the administration of S-1) in the former case and 3 years from the initial visit (2 years and 1 month from the start of the administration of S-1) in the latter case.
  • [MeSH-major] Antimetabolites, Antineoplastic / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Aged, 80 and over. Drug Combinations. Humans. Male. Quality of Life

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19620804.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antimetabolites, Antineoplastic; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


18. Dilkes MG, Benjamin E, Ovaisi S, Banerjee AS: Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases. J Laryngol Otol; 2003 Sep;117(9):713-7
MedlinePlus Health Information. consumer health - Head and Neck Cancer.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Treatment of primary mucosal head and neck squamous cell carcinoma using photodynamic therapy: results after 25 treated cases.
  • The use of photodynamic therapy for the treatment of malignant and non-malignant conditions is increasing.
  • This paper demonstrates the efficacy of a second-generation photosensitizer, Foscan, in the primary treatment of a wide range of mucosal head and neck squamous cell carcinomas.
  • A complete response to primary treatment was seen in 19/21 patients (90 per cent).
  • In laryngeal cancer recurrent after radical radiotherapy, one out of four patients treated obtained a complete response (25 per cent).
  • Six patients (24 per cent) required surgery after photodynamic therapy, for local recurrence or dysplasia.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Mesoporphyrins / administration & dosage. Neoplasm Recurrence, Local / drug therapy. Photochemotherapy / methods. Photosensitizing Agents / administration & dosage
  • [MeSH-minor] Combined Modality Therapy. Follow-Up Studies. Humans. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Mouth Neoplasms / drug therapy. Mouth Neoplasms / radiotherapy. Mouth Neoplasms / surgery. Oropharyngeal Neoplasms / drug therapy. Oropharyngeal Neoplasms / radiotherapy. Oropharyngeal Neoplasms / surgery. Retrospective Studies. Treatment Outcome

  • Genetic Alliance. consumer health - Carcinoma, Squamous Cell.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 14561360.001).
  • [ISSN] 0022-2151
  • [Journal-full-title] The Journal of laryngology and otology
  • [ISO-abbreviation] J Laryngol Otol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] England
  • [Chemical-registry-number] 0 / Mesoporphyrins; 0 / Photosensitizing Agents; FU21S769PF / temoporfin
  •  go-up   go-down


19. Lesinski-Schiedat A, Hemmanouil I, Sauer-Gönen M, Flemming P, Freihorst I, Kempf HG, Lenarz T: [Malignant transformation of a juvenile papilloma in a 11 year old boy]. Laryngorhinootologie; 2005 Aug;84(8):602-7

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Malignant transformation of a juvenile papilloma in a 11 year old boy].
  • BACKGROUND: The juvenile laryngeal papilloma is the most common benign neoplasm in children.
  • Often the entity shows an elongated recurrent course of disease with an expansion into the tracheo-bronchial system.
  • Sporadic malignant transformation in adults with a papilloma was reported after treatment with radiotherapy alone or in combination with the intake of additional toxins (e. g. nicotine).
  • Similar reports of a malignant transformation of juvenile papillomas without additional risk factors is very rarely reported.
  • CASE REPORT: We report about an 11 year old boy, who suffered from a juvenile laryngeal papilloma.
  • The multiple laser surgical procedures and a therapy with interferon resulted in a short-term remissions.
  • Seven months after the first diagnosis of the papilloma a regional metastatic squamous cell carcinoma was found.
  • In spite of combined radiotherapy and chemotherapy the boy died 11 months later.
  • CONCLUSIONS: The spontaneous malignant transformation of a juvenile papilloma in a squamous cell carcinoma is extremely rare.
  • The surgical intervention as well the radiotherapy and chemotherapy using interferon was unsuccessful due to the high grade of malignancy.
  • In view of the very short time interval between first diagnosis of juvenile papilloma and the subsequent malignant transformation, one must consider either the potential presence of a very aggressive form of papilloma or alternative two coincident independent diseases.
  • [MeSH-major] Carcinoma, Squamous Cell / pathology. Cell Transformation, Neoplastic / pathology. Laryngeal Neoplasms / pathology. Papilloma / pathology
  • [MeSH-minor] Antineoplastic Agents / therapeutic use. Child. Humans. Interferons / therapeutic use. Magnetic Resonance Imaging. Male. Remission Induction. Time Factors

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 16080063.001).
  • [ISSN] 0935-8943
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 9008-11-1 / Interferons
  •  go-up   go-down


20. Mukherji SK, Weadock WJ: Imaging of the post-treatment larynx. Eur J Radiol; 2002 Nov;44(2):108-19

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Imaging of the post-treatment larynx.
  • The treatment for squamous cell carcinoma of the upper aerodigestive tract includes surgery, radiation therapy (RT), chemotherapy or a combination of various modalities.
  • Familiarization with the expected imaging changes following therapy allow accurate evaluation of imaging studies and may prevent misinterpretation of post-treatment changes as recurrent disease.
  • The intent of this manuscript will be to review the post-treatment appearance of the larynx following RT and various types of laryngectomy.
  • [MeSH-major] Carcinoma, Squamous Cell / radiotherapy. Carcinoma, Squamous Cell / surgery. Laryngeal Neoplasms / radiotherapy. Laryngeal Neoplasms / surgery. Larynx / radiography. Neoplasm Recurrence, Local / radiography
  • [MeSH-minor] Combined Modality Therapy. Diagnosis, Differential. Humans. Tomography, X-Ray Computed

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12413679.001).
  • [ISSN] 0720-048X
  • [Journal-full-title] European journal of radiology
  • [ISO-abbreviation] Eur J Radiol
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] Ireland
  • [Number-of-references] 17
  •  go-up   go-down


21. Swanson SJ, Batirel HF, Bueno R, Jaklitsch MT, Lukanich JM, Allred E, Mentzer SJ, Sugarbaker DJ: Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma. Ann Thorac Surg; 2001 Dec;72(6):1918-24; discussion 1924-5
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Transthoracic esophagectomy with radical mediastinal and abdominal lymph node dissection and cervical esophagogastrostomy for esophageal carcinoma.
  • This study examines the morbidity, mortality, and early survival of patients after transthoracic esophagectomy for esophageal carcinoma using current staging techniques and neoadjuvant therapy.
  • METHODS: Three hundred forty-two patients had surgery for esophageal carcinoma between 1989 and 2000 at our institution.
  • Eighty-one percent (202) had induction chemotherapy (all patients with clinical T3/4 or N1).
  • Early postoperative complications included recurrent laryngeal nerve injury (14% [35]), chylothorax (9%, [22]), and leak (8%, [19]).
  • CONCLUSIONS: Total thoracic esophagectomy with node dissection for esophageal cancer appears to have acceptable morbidity and mortality with encouraging survival results in the setting of neoadjuvant therapy.
  • [MeSH-major] Adenocarcinoma / surgery. Barrett Esophagus / surgery. Carcinoma, Squamous Cell / surgery. Esophageal Neoplasms / surgery. Esophagectomy / methods. Gastrostomy / methods. Lymph Node Excision / methods. Precancerous Conditions / surgery

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 11789772.001).
  • [ISSN] 0003-4975
  • [Journal-full-title] The Annals of thoracic surgery
  • [ISO-abbreviation] Ann. Thorac. Surg.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


22. Patel RS, Makitie AA, Goldstein DP, Gullane PJ, Brown D, Irish J, Gilbert RW: Morbidity and functional outcomes following gastro-omental free flap reconstruction of circumferential pharyngeal defects. Head Neck; 2009 May;31(5):655-63
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • BACKGROUND: In patients with extensive soft tissue fibrosis requiring circumferential pharyngeal reconstruction following definitive radiotherapy and/or chemotherapy, we take advantage of abundant omental progenitor factors in the tubed gastro-omental free flap.
  • METHODS: Review of 11 patients (median follow-up, 2.8 years) undergoing total pharyngolaryngectomy following organ preservation protocols for recurrent squamous cell carcinoma (n = 9) and stricture (n = 2).
  • [MeSH-minor] Aged. Carcinoma, Squamous Cell / mortality. Carcinoma, Squamous Cell / surgery. Constriction, Pathologic / surgery. Female. Fistula / etiology. Fistula / surgery. Follow-Up Studies. Gastric Mucosa / blood supply. Gastric Mucosa / transplantation. Gastric Outlet Obstruction / etiology. Gastric Outlet Obstruction / therapy. Hematoma / etiology. Hematoma / surgery. Hernia, Abdominal / etiology. Hernia, Abdominal / surgery. Humans. Hypopharyngeal Neoplasms / mortality. Hypopharyngeal Neoplasms / surgery. Laryngeal Neoplasms / mortality. Laryngeal Neoplasms / surgery. Larynx, Artificial. Length of Stay. Male. Middle Aged. Neoplasm Recurrence, Local / surgery. Omentum / blood supply. Omentum / transplantation. Pulmonary Embolism / drug therapy. Pulmonary Embolism / surgery. Salvage Therapy. Surgical Wound Dehiscence / etiology. Surgical Wound Dehiscence / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19260110.001).
  • [ISSN] 1097-0347
  • [Journal-full-title] Head & neck
  • [ISO-abbreviation] Head Neck
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


23. Wakisaka N, Murono S, Kondo S, Furukawa M, Yoshizaki T: Post-operative pharyngocutaneous fistula after laryngectomy. Auris Nasus Larynx; 2008 Jun;35(2):203-8
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • OBJECTIVES: Although organ-preserving radiotherapy or chemoradiotherapy has offered good locoregional control, many patients still experience recurrent disease requiring salvage laryngectomy.
  • Here, we evaluated the cause of PCF after laryngectomy, with special emphasis on radiotherapy and/or chemotherapy.
  • PATIENTS AND METHODS: A total of 63 consecutive patients undergoing salvage total laryngectomy for squamous cell carcinoma of the larynx at Kanazawa University Hospital from 1990 to 2005 were reviewed.
  • RESULTS: Overall, 17 of the 63 patients (27.0%) developed PCF after laryngectomy.
  • CONCLUSIONS: Although radiotherapy or chemotherapy has only a limited impact on PCF formation, concurrent chemoradiotherapy significantly increases PCF formation.
  • The addition of chemotherapy to irradiation delays PCF closure.
  • [MeSH-minor] Carcinoma, Squamous Cell / therapy. Chemotherapy, Adjuvant / adverse effects. Female. Humans. Laryngeal Neoplasms / therapy. Male. Middle Aged. Postoperative Complications. Radiotherapy, Adjuvant / adverse effects. Salvage Therapy

  • MedlinePlus Health Information. consumer health - Throat Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 17826021.001).
  • [ISSN] 0385-8146
  • [Journal-full-title] Auris, nasus, larynx
  • [ISO-abbreviation] Auris Nasus Larynx
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Netherlands
  •  go-up   go-down


24. Annino DJ Jr, Goguen LA: Mitomycin C for the treatment of pharyngoesophageal stricture after total laryngopharyngectomy and microvascular free tissue reconstruction. Laryngoscope; 2003 Sep;113(9):1499-502
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Mitomycin C for the treatment of pharyngoesophageal stricture after total laryngopharyngectomy and microvascular free tissue reconstruction.
  • STUDY DESIGN: Five patients since 1998 underwent evaluation and treatment for pharyngoesophageal stricture after total laryngopharyngectomy and free flap reconstruction.
  • All patients underwent barium swallow, computed tomography, and endoscopic examination and were proven to be free of recurrent disease.
  • All patients were happy with the treatment results.
  • CONCLUSIONS: This small case series suggests that MMC is a safe and effective adjunctive treatment for pharyngoesophageal stricture after total laryngopharyngectomy and free flap reconstruction.
  • [MeSH-major] Esophageal Stenosis / drug therapy. Laryngectomy. Microsurgery. Mitomycin / administration & dosage. Nucleic Acid Synthesis Inhibitors / administration & dosage. Pharyngeal Diseases / drug therapy. Pharyngectomy. Postoperative Complications / drug therapy. Surgical Flaps / blood supply
  • [MeSH-minor] Adenocarcinoma / surgery. Administration, Topical. Aged. Carcinoma, Squamous Cell / surgery. Combined Modality Therapy. Constriction, Pathologic / diagnosis. Constriction, Pathologic / drug therapy. Deglutition Disorders / diagnosis. Deglutition Disorders / drug therapy. Dilatation. Esophageal Neoplasms / surgery. Esophagoscopy. Female. Humans. Laryngeal Neoplasms / surgery. Male. Pharyngeal Neoplasms / surgery. Treatment Outcome

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Throat Disorders.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 12972923.001).
  • [ISSN] 0023-852X
  • [Journal-full-title] The Laryngoscope
  • [ISO-abbreviation] Laryngoscope
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Nucleic Acid Synthesis Inhibitors; 50SG953SK6 / Mitomycin
  •  go-up   go-down


25. Jiang YY, Wu SX, Zhang P, Xie CY, Wang J, Sun CC: [Concurrent standard dose of cisplatin, paclitaxel, and radiotherapy followed by surgery in treatment of thoracic esophageal carcinoma]. Zhonghua Yi Xue Za Zhi; 2008 Aug 12;88(31):2171-4
Hazardous Substances Data Bank. TAXOL .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Concurrent standard dose of cisplatin, paclitaxel, and radiotherapy followed by surgery in treatment of thoracic esophageal carcinoma].
  • OBJECTIVE: To investigate the curative effect of incorporation of the regimen of standard dose of paclitaxel combined with cisplatin into concurrent radiotherapy as pre-operative treatment for patients with esophageal carcinoma.
  • METHODS: Twenty-six patients with primary diagnosis of esophageal carcinoma, 17 in stage II and 9 in stage III, underwent conventional fractionated radiotherapy with a total dosage of 40 Gy (2 Gy per day, 5 doses per week).
  • Surgery-related complications included anastomotic leakage (3.85%, 1/26), recurrent laryngeal nerve injury (7.69%, 2/26), and chylothorax (3.85%, 1/26).
  • CONCLUSION: Preoperative chemoradiotherapy containing full dose of paclitaxel and cisplatin increases the 5-year overall survival for the patients with postoperative pathologic response grade II and above, and does not increase the treatment-related complications.
  • [MeSH-major] Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / therapy. Esophageal Neoplasms / therapy
  • [MeSH-minor] Adult. Aged. Cisplatin / administration & dosage. Combined Modality Therapy. Drug Administration Schedule. Esophagectomy. Female. Follow-Up Studies. Humans. Kaplan-Meier Estimate. Male. Middle Aged. Paclitaxel / administration & dosage. Radiotherapy. Young Adult

  • MedlinePlus Health Information. consumer health - Esophageal Cancer.
  • Hazardous Substances Data Bank. CIS-DIAMINEDICHLOROPLATINUM .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19080664.001).
  • [ISSN] 0376-2491
  • [Journal-full-title] Zhonghua yi xue za zhi
  • [ISO-abbreviation] Zhonghua Yi Xue Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  • [Chemical-registry-number] P88XT4IS4D / Paclitaxel; Q20Q21Q62J / Cisplatin
  •  go-up   go-down


26. Biel MA: Photodynamic therapy of head and neck cancers. Methods Mol Biol; 2010;635:281-93
COS Scholar Universe. author profiles.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Photodynamic therapy of head and neck cancers.
  • These patients include a mixture of presentations including primary, recurrent, and metastatic lesions.
  • The predominant histology is squamous cell carcinoma, but other histologies treated include mucosal melanoma, Kaposi's sarcoma, adenocarcinoma, metastatic breast carcinoma, and adenoid cystic carcinoma.
  • Several multi-institutional phase II clinical trials evaluating PDT treatment of head and neck cancers have demonstrated the efficacy of this minimally invasive therapy in the treatment of early oropharyngeal primary and recurrent cancers as well as the palliative treatment of refractory head and neck cancers.
  • Patients with early stage cancers or early recurrences in the oral cavity and larynx (Cis, T1, T2) tend to have an excellent response to PDT.
  • Of 518 patients treated with Cis, T1, or T2 cancers of the oral cavity, larynx, pharynx, and nasopharynx, 462 (89.1%) obtained a complete clinical response after one PDT treatment.
  • Laryngeal cancers, comprising 171 patients in this group, obtained a durable complete response rate of 89% with up to a 16-year follow-up.
  • Photodynamic therapy is as effective as conventional therapies for the treatment of early (Cis, T1, T2) squamous cell cancers of the head and neck.
  • It is also a promising therapy to be used in association with surgery to increase tumor-free margins and therefore increase cure rates.
  • [MeSH-major] Head and Neck Neoplasms / drug therapy. Photochemotherapy
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Female. Humans. Male. Middle Aged. Randomized Controlled Trials as Topic. Treatment Outcome. Young Adult

  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 20552353.001).
  • [ISSN] 1940-6029
  • [Journal-full-title] Methods in molecular biology (Clifton, N.J.)
  • [ISO-abbreviation] Methods Mol. Biol.
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  •  go-up   go-down


27. Albers AE, Hoffmann TK, Klussmann JP, Kaufmann AM: [Prophylactic and therapeutic vaccines against human papilloma virus]. HNO; 2010 Aug;58(8):778-90

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Prophylactic and therapeutic vaccines against human papilloma virus].
  • Infection with human papilloma virus (HPV) has been identified as the cause of recurrent papillomatosis and of a subgroup of squamous cell carcinomas of the head and neck.
  • A change in prevalence of these lesions, especially for oropharyngeal carcinoma, can be expected as a consequence of the introduction of prophylactic HPV vaccines for young women, targeting the most frequent high- and low-risk HPV subtypes.
  • Vaccination for the major low-risk HPV types has proven to be highly effective against genital warts and activity against papillomatosis can be expected.
  • The possibilities of prophylactic HPV vaccination as well as new developments and the rationale for therapeutic vaccines are discussed on the basis of the current literature.
  • [MeSH-major] Carcinoma, Squamous Cell / drug therapy. Carcinoma, Squamous Cell / prevention & control. Otorhinolaryngologic Neoplasms / drug therapy. Otorhinolaryngologic Neoplasms / prevention & control. Papilloma / drug therapy. Papilloma / prevention & control. Papillomavirus Vaccines / therapeutic use
  • [MeSH-minor] Adolescent. Adult. Antibody Formation / immunology. Child. Condylomata Acuminata / drug therapy. Condylomata Acuminata / immunology. Condylomata Acuminata / prevention & control. Female. Human papillomavirus 11 / immunology. Human papillomavirus 16 / immunology. Human papillomavirus 18 / immunology. Human papillomavirus 6 / immunology. Humans. Immunity, Cellular / immunology. Laryngeal Neoplasms / drug therapy. Laryngeal Neoplasms / immunology. Laryngeal Neoplasms / prevention & control. Risk Factors. Treatment Outcome. Young Adult

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Clin Cancer Res. 2000 Sep;6(9):3406-16 [10999722.001]
  • [Cites] J Infect Dis. 2005 Dec 15;192(12):2099-107 [16288373.001]
  • [Cites] Clin Otolaryngol. 2006 Aug;31(4):259-66 [16911640.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2003 Apr;112(4):298-302 [12731623.001]
  • [Cites] J Clin Oncol. 2006 Dec 20;24(36):5630-6 [17179101.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2003 Jun;12(6):485-90 [12814991.001]
  • [Cites] Lancet. 2004 May 8;363(9420):1488-9 [15135592.001]
  • [Cites] Lancet Oncol. 2005 Apr;6(4):204 [15830458.001]
  • [Cites] J Immunother. 2000 Mar-Apr;23(2):255-66 [10746552.001]
  • [Cites] Clin Cancer Res. 2004 May 1;10(9):2954-61 [15131030.001]
  • [Cites] Adv Otorhinolaryngol. 2005;62:161-72 [15608426.001]
  • [Cites] Cancer. 1999 May 1;85(9):1903-9 [10223228.001]
  • [Cites] J Infect Dis. 2005 Jan 15;191(2):182-92 [15609227.001]
  • [Cites] J Clin Microbiol. 2006 Dec;44(12):4479-85 [17021055.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2005 Feb;14(2):467-75 [15734974.001]
  • [Cites] Head Neck. 2009 Jul;31(7):893-901 [19283851.001]
  • [Cites] Int J Cancer. 2007 Apr 15;120(8):1731-8 [17236202.001]
  • [Cites] Lancet. 2009 Jun 6;373(9679):1921-2 [19501728.001]
  • [Cites] J Natl Cancer Inst. 2005 Jul 20;97(14):1066-71 [16030304.001]
  • [Cites] Int J Cancer. 2000 Feb 1;85(3):313-8 [10652419.001]
  • [Cites] IARC Sci Publ. 1992;(119):25-52 [1330914.001]
  • [Cites] Vaccine. 2006 Jul 7;24(27-28):5571-83 [16753240.001]
  • [Cites] Obstet Gynecol. 1999 Apr;93(4):475-9 [10214817.001]
  • [Cites] J Infect Dis. 1999 Nov;180(5):1415-23 [10515798.001]
  • [Cites] Int J Cancer. 2004 Feb 20;108(5):766-72 [14696105.001]
  • [Cites] JAMA. 2007 Aug 15;298(7):743-53 [17699008.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S16-24 [15753008.001]
  • [Cites] Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):324-7 [14973086.001]
  • [Cites] Int J Cancer. 2003 Apr 10;104(3):336-44 [12569557.001]
  • [Cites] Gynecol Oncol. 2005 Jan;96(1):92-102 [15589586.001]
  • [Cites] Curr Opin Oncol. 2001 May;13(3):183-8 [11307062.001]
  • [Cites] J Natl Cancer Inst. 2008 Feb 20;100(4):261-9 [18270337.001]
  • [Cites] Curr Opin Oncol. 1999 May;11(3):191-9 [10328594.001]
  • [Cites] J Natl Cancer Inst. 2004 Mar 17;96(6):449-55 [15026470.001]
  • [Cites] Int J Pediatr Otorhinolaryngol. 2006 Oct;70(10):1799-803 [16884786.001]
  • [Cites] CA Cancer J Clin. 2005 Mar-Apr;55(2):74-108 [15761078.001]
  • [Cites] Vaccine. 2009 Jul 23;27(34):4551-9 [19524337.001]
  • [Cites] Vaccine. 1999 Jan;17(1):40-9 [10078606.001]
  • [Cites] Pediatr Infect Dis J. 2007 Nov;26(11):979-84 [17984802.001]
  • [Cites] Int J Cancer. 2006 Feb 1;118(3):675-83 [16108057.001]
  • [Cites] Cancer Res. 2002 Jan 15;62(2):472-9 [11809698.001]
  • [Cites] Br J Cancer. 2005 Mar 14;92(5):913-20 [15714205.001]
  • [Cites] N Engl J Med. 2001 Apr 12;344(15):1125-31 [11297703.001]
  • [Cites] Ann Transplant. 1997;2(4):59-66 [9869880.001]
  • [Cites] Public Health Genomics. 2009;12(5-6):331-42 [19684445.001]
  • [Cites] J Clin Oncol. 2006 Jun 10;24(17):2606-11 [16763272.001]
  • [Cites] Am J Pathol. 2003 Mar;162(3):747-53 [12598309.001]
  • [Cites] Cancer Res. 2005 Dec 1;65(23):11146-55 [16322265.001]
  • [Cites] Lancet. 2007 Jun 30;369(9580):2161-2170 [17602732.001]
  • [Cites] Eur J Cancer B Oral Oncol. 1996 Jan;32B(1):55-62 [8729620.001]
  • [Cites] J Natl Cancer Inst. 2001 Feb 21;93(4):252-3 [11181763.001]
  • [Cites] Lancet. 2004 Nov 13-19;364(9447):1757-65 [15541448.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1749-55 [17582606.001]
  • [Cites] Hematol Oncol Clin North Am. 1999 Feb;13(1):259-73 [10080080.001]
  • [Cites] J Cancer Res Clin Oncol. 2003 Sep;129(9):521-30 [12898233.001]
  • [Cites] Am J Med. 1997 May 5;102(5A):3-8 [9217656.001]
  • [Cites] Cancer Immunol Immunother. 2004 Jul;53(7):642-50 [14985860.001]
  • [Cites] Hum Gene Ther. 2004 May;15(5):421-31 [15144573.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):453-60 [17586030.001]
  • [Cites] Internist (Berl). 2009 May;50(5):617-26 [19384543.001]
  • [Cites] Clin Cancer Res. 2002 May;8(5):1028-37 [12006515.001]
  • [Cites] J Pathol. 1999 Sep;189(1):12-9 [10451482.001]
  • [Cites] Lancet. 2006 Apr 15;367(9518):1247-55 [16631880.001]
  • [Cites] J Infect Dis. 2000 Jun;181(6):1911-9 [10837170.001]
  • [Cites] Int J Cancer. 2007 Dec 15;121(12):2794-800 [17721997.001]
  • [Cites] Cancer Immunol Immunother. 2005 Nov;54(11):1072-81 [15959774.001]
  • [Cites] Sex Transm Dis. 2006 Aug;33(8):502-8 [16572039.001]
  • [Cites] Front Biosci. 2003 May 01;8:s333-45 [12700045.001]
  • [Cites] N Engl J Med. 2003 Feb 6;348(6):518-27 [12571259.001]
  • [Cites] Immunol Rev. 1999 Apr;168:131-42 [10399070.001]
  • [Cites] Clin Cancer Res. 2007 Nov 1;13(21):6301-11 [17975141.001]
  • [Cites] N Engl J Med. 2002 Nov 21;347(21):1645-51 [12444178.001]
  • [Cites] Cancer Res. 2003 Sep 15;63(18):6032-41 [14522932.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2005 Sep;114(9):730-7 [16240938.001]
  • [Cites] Laryngoscope. 2001 Sep;111(9):1639-44 [11568620.001]
  • [Cites] J Infect Dis. 2007 Oct 15;196(8):1153-62 [17955433.001]
  • [Cites] Expert Rev Vaccines. 2008 Dec;7(10):1465-73 [19053203.001]
  • [Cites] Head Neck. 2009 Mar;31(3):371-80 [19073006.001]
  • [Cites] HNO. 2009 Feb;57(2):113-22 [19194683.001]
  • [Cites] J Med Microbiol. 2001 May;50(5):468-71 [11339256.001]
  • [Cites] J Natl Cancer Inst. 1998 Nov 4;90(21):1626-36 [9811312.001]
  • [Cites] J Infect Dis. 1999 Mar;179(3):612-8 [9952367.001]
  • [Cites] Clin Cancer Res. 2004 Jun 1;10(11):3755-62 [15173082.001]
  • [Cites] Clin Exp Dermatol. 2002 Oct;27(7):571-7 [12464152.001]
  • [Cites] Clin Cancer Res. 2002 Dec;8(12):3676-85 [12473576.001]
  • [Cites] Nat Rev Cancer. 2002 May;2(5):342-50 [12044010.001]
  • [Cites] Am J Obstet Gynecol. 2003 Apr;188(4):916-26 [12712086.001]
  • [Cites] Dtsch Med Wochenschr. 2009 Apr;134 Suppl 2:S100-2 [19353471.001]
  • [Cites] J Natl Cancer Inst Monogr. 2003;(31):14-9 [12807940.001]
  • [Cites] CMAJ. 2003 Sep 2;169(5):431-4 [12952805.001]
  • [Cites] J Pediatr. 1998 Feb;132(2):277-84 [9506641.001]
  • [Cites] Arch Otolaryngol Head Neck Surg. 1995 Dec;121(12):1386-91 [7488368.001]
  • [Cites] N Engl J Med. 1993 Jan 21;328(3):184-94 [8417385.001]
  • [Cites] Dis Colon Rectum. 2002 Apr;45(4):502-7 [12006932.001]
  • [Cites] Clin Cancer Res. 2008 Jun 15;14(12):3706-15 [18559587.001]
  • [Cites] Exp Mol Pathol. 2000 Jun;68(3):147-51 [10816383.001]
  • [Cites] Cancer Res. 2003 Feb 1;63(3):636-41 [12566307.001]
  • [Cites] Hum Gene Ther. 2002 Jun 10;13(9):1127-40 [12067445.001]
  • [Cites] J Virol. 2008 Feb;82(4):1968-79 [18057249.001]
  • [Cites] J Clin Virol. 2005 Mar;32 Suppl 1:S59-66 [15753013.001]
  • [Cites] AIDS. 2006 May 12;20(8):1151-5 [16691066.001]
  • [Cites] Vaccine. 2002 Oct 4;20(29-30):3456-64 [12297390.001]
  • [Cites] Ann Otol Rhinol Laryngol. 2000 Nov;109(11):1069-76 [11090000.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1993 Dec;18(6):470-4 [8877222.001]
  • [Cites] Lancet. 1996 Jun 1;347(9014):1523-7 [8684105.001]
  • [Cites] Cancer Gene Ther. 2006 Jun;13(6):592-7 [16456551.001]
  • [Cites] Am J Obstet Gynecol. 2008 Mar;198(3):261.e1-11 [18313445.001]
  • [Cites] N Engl J Med. 1993 Jun 17;328(24):1783; author reply 1784 [8497290.001]
  • [Cites] Laryngorhinootologie. 2008 Nov;87(11):796-9 [18759217.001]
  • [Cites] Obstet Gynecol. 2004 Feb;103(2):317-26 [14754702.001]
  • [Cites] Dis Markers. 2007;23(4):337-52 [17627067.001]
  • [Cites] Cancer Res. 2004 Aug 1;64(15):5449-55 [15289354.001]
  • [Cites] Vaccine. 2003 Oct 1;21(27-30):4256-60 [14505907.001]
  • [Cites] J Natl Cancer Inst. 2003 Sep 3;95(17):1336-43 [12953088.001]
  • [Cites] J Infect Dis. 2004 Feb 15;189(4):686-98 [14767823.001]
  • [Cites] Cancer Res. 2007 Sep 15;67(18):8865-73 [17875728.001]
  • [Cites] Clin Cancer Res. 2003 Nov 1;9(14):5205-13 [14614000.001]
  • [Cites] Br J Cancer. 2003 Jan 13;88(1):63-73 [12556961.001]
  • [Cites] Clin Otolaryngol Allied Sci. 1986 Dec;11(6):423-9 [3815867.001]
  • [Cites] J Natl Cancer Inst. 2005 Dec 21;97(24):1816-21 [16368943.001]
  • [Cites] Int J Gynecol Cancer. 2006 May-Jun;16(3):1075-81 [16803488.001]
  • [Cites] Otolaryngol Head Neck Surg. 2005 Mar;132(3):392-4 [15746849.001]
  • [Cites] Int J Cancer. 2006 Apr 15;118(8):1984-91 [16284959.001]
  • [Cites] Am J Clin Pathol. 1994 Dec;102(6):768-74 [7801889.001]
  • [Cites] Vaccine. 2004 Nov 25;23(2):172-81 [15531034.001]
  • [Cites] Laryngoscope. 2004 Nov;114(11 Pt 2 Suppl 104):1-23 [15514560.001]
  • [Cites] Gynecol Oncol. 2007 Sep;106(3):558-66 [17631950.001]
  • [Cites] Vaccine. 2003 Jan 30;21(7-8):787-90 [12531360.001]
  • [Cites] Acta Otolaryngol. 2004 May;124(4):520-6 [15224887.001]
  • [Cites] Clin Cancer Res. 1998 Sep;4(9):2103-9 [9748126.001]
  • [Cites] Lancet Oncol. 2005 May;6(5):271-8 [15863374.001]
  • [Cites] J Natl Cancer Inst. 2000 May 3;92(9):709-20 [10793107.001]
  • [Cites] Clin Immunol. 2001 Oct;101(1):94-9 [11580231.001]
  • [Cites] N Engl J Med. 2002 May 30;346(22):1752-3 [12037163.001]
  • [Cites] Clin Cancer Res. 2008 Jan 1;14(1):169-77 [18172268.001]
  • [Cites] Vaccine. 2004 Jul 29;22(21-22):2722-9 [15246603.001]
  • [Cites] Obstet Gynecol. 2006 Jan;107(1):18-27 [16394035.001]
  • (PMID = 20544168.001).
  • [ISSN] 1433-0458
  • [Journal-full-title] HNO
  • [ISO-abbreviation] HNO
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article; Review
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Papillomavirus Vaccines; Laryngeal papillomatosis
  •  go-up   go-down


28. Abo H, Tsukuda M, Matsuda H, Horiuchi C, Taguchi T, Watanabe M, Niho T: [Successful treatment results of S-1 administration in 2 patients, one with a remnant tumor of the larynx and metastatic tumors to the lung, and another with a metastatic tumor in the neck from the hypopharynx]. Gan To Kagaku Ryoho; 2009 Oct;36(10):1707-9
NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Successful treatment results of S-1 administration in 2 patients, one with a remnant tumor of the larynx and metastatic tumors to the lung, and another with a metastatic tumor in the neck from the hypopharynx].
  • We report two successful remnant and recurrent cases of head and neck cancer treated with S-1.
  • Case 1, a 52-year-old man, was diagnosed as supraglottic laryngeal carcinoma (T3N2cM0, squamous cell carcinoma: SCC) on January 25, 2000, and concurrent chemoradiotherapy (CCRT) was applied.
  • After the treatment, a remnant tumor in the larynx was found by biopsy.
  • Pulmonary metastasis was detected by chest CT on June 14, 2001, and the administration of S-1 was started.
  • The administration of S-1 is still continuing and remnant tumors have not been found.
  • Case 2, a 76-year-old man, was diagnosed with hypopharyngeal carcinoma (T3N2bM0, SCC) on December 14, 2001, and CCRT was applied resulting in CR in the hypopharynx and the neck.
  • [MeSH-major] Antineoplastic Agents / therapeutic use. Antineoplastic Combined Chemotherapy Protocols / therapeutic use. Carcinoma, Squamous Cell / drug therapy. Head and Neck Neoplasms / drug therapy. Hypopharyngeal Neoplasms / drug therapy. Laryngeal Neoplasms / drug therapy. Lung Neoplasms / drug therapy. Oxonic Acid / therapeutic use. Tegafur / therapeutic use
  • [MeSH-minor] Aged. Drug Combinations. Humans. Male. Middle Aged. Tomography, X-Ray Computed. Treatment Outcome

  • MedlinePlus Health Information. consumer health - Cancer Chemotherapy.
  • MedlinePlus Health Information. consumer health - Head and Neck Cancer.
  • MedlinePlus Health Information. consumer health - Lung Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 19838032.001).
  • [ISSN] 0385-0684
  • [Journal-full-title] Gan to kagaku ryoho. Cancer & chemotherapy
  • [ISO-abbreviation] Gan To Kagaku Ryoho
  • [Language] jpn
  • [Publication-type] Case Reports; English Abstract; Journal Article
  • [Publication-country] Japan
  • [Chemical-registry-number] 0 / Antineoplastic Agents; 0 / Drug Combinations; 150863-82-4 / S 1 (combination); 1548R74NSZ / Tegafur; 5VT6420TIG / Oxonic Acid
  •  go-up   go-down


29. Bast F, Risteska K, Jovanovic S, Sedlmaier B: [The topical application of mitomycin C in the treatment of scar formation and stenosis in hollow organs of the head and neck: a field report]. Laryngorhinootologie; 2009 Aug;88(8):528-33
Hazardous Substances Data Bank. MITOMYCIN C .

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [The topical application of mitomycin C in the treatment of scar formation and stenosis in hollow organs of the head and neck: a field report].
  • Besides its use as an adjunction in the treatment of breast, lung and prostate cancer, or as a second-line cytostatic drug for head and neck squamous cell carcinoma (HNSCC), since 1963, MMC has also been successfully used in the suppression of post-operative scar formation, particularly in the field of ophthalmology.
  • In this résumé, we wish to recapitulate our long years of experience in the topical application of Mitomycin C in the treatment of scar formation and stenosis in head and neck organs.
  • The fields of application included laryngeal, tracheal, oesophageal stenosis and stenosis of the external ear canal and the choane.
  • RESULTS: After combined application of MMC and surgical intervention in cases of recurrent stenosising processes in head and neck organs, especially the larynx and the trachea, a sustained improvement was achieved in the pre-operative stenosis level as well as in the pre-operative, severely limited, forced inspiratory volume in 1 second (F1V1).
  • CONCLUSION: The topical application of MMC appears to be an effective adjunction as a concept of treatment for stenosising, scar-forming lesions.
  • This topical application, however, is not a substitute for correct diagnosis and appropriate surgical treatment.
  • [MeSH-major] Airway Obstruction / drug therapy. Antibiotics, Antineoplastic / administration & dosage. Cicatrix / drug therapy. Mitomycin / administration & dosage. Postoperative Complications / drug therapy
  • [MeSH-minor] Administration, Topical. Adolescent. Adult. Aged. Aged, 80 and over. Child. Child, Preschool. Combined Modality Therapy. Female. Humans. Inspiratory Capacity / drug effects. Laryngoscopy. Laryngostenosis / diagnosis. Laryngostenosis / drug therapy. Laryngostenosis / surgery. Laser Therapy. Male. Middle Aged. Recurrence. Reoperation. Retreatment. Retrospective Studies. Tracheal Stenosis / diagnosis. Tracheal Stenosis / drug therapy. Tracheal Stenosis / surgery

  • MedlinePlus Health Information. consumer health - After Surgery.
  • MedlinePlus Health Information. consumer health - Choking.
  • MedlinePlus Health Information. consumer health - Scars.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Copyright] Georg Thieme Verlag KG Stuttgart, New York.
  • (PMID = 19554503.001).
  • [ISSN] 1438-8685
  • [Journal-full-title] Laryngo- rhino- otologie
  • [ISO-abbreviation] Laryngorhinootologie
  • [Language] ger
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] Germany
  • [Chemical-registry-number] 0 / Antibiotics, Antineoplastic; 50SG953SK6 / Mitomycin
  •  go-up   go-down


30. Liu WS, Tang PZ, Qi YF, Xu ZG, Li ZJ: [Clinical analysis of 57 patients with poorly differentiated carcinomas of the supraglottic larynx]. Zhonghua Er Bi Yan Hou Ke Za Zhi; 2004 Sep;39(9):562-5

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] [Clinical analysis of 57 patients with poorly differentiated carcinomas of the supraglottic larynx].
  • OBJECTIVE: To investigate the clinical characteristics, treatment and prognosis for poorly differentiated supraglottic carcinomas.
  • Of the 57 patients, 25 were treated with surgery alone, 9 with irradiation alone, 14 with surgery following preoperative radiation, 7 with postoperative radiation following surgery and 2 with surgery following preoperative chemotherapy.
  • RESULTS: The overall 5-year survival rate, accumulated cervical metastasis rate, metastasis rate of bilateral side of neck, distant metastasis rate, cervical recurrent rate and locally recurrent rate were 47.4% (27/57), 63.2% (36/57), 24.6% (14/57), 21.1% (12/57), 28.1% (16/57) and 10.5% (6/57), respectively.
  • In addition, the local recurrent rate for partial laryngectomy was 12% (3/25).
  • CONCLUSIONS: Poorly differentiated carcinomas of the supraglottic larynx had characteristics of the advanced stage in terms of earlier lymph node metastasis and a relatively high rate of cervical and distant metastasis.
  • Surgery was still the primary treatment for this disease and it was feasible to perform partial laryngectomy on certain patients.
  • [MeSH-major] Carcinoma, Squamous Cell / surgery. Glottis / surgery. Laryngeal Neoplasms / surgery
  • [MeSH-minor] Adult. Aged. Aged, 80 and over. Combined Modality Therapy. Female. Humans. Laryngectomy. Male. Middle Aged. Neoplasm Metastasis. Retrospective Studies. Survival Rate

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15606009.001).
  • [ISSN] 0412-3948
  • [Journal-full-title] Zhonghua er bi yan hou ke za zhi
  • [ISO-abbreviation] Zhonghua Er Bi Yan Hou Ke Za Zhi
  • [Language] chi
  • [Publication-type] English Abstract; Journal Article
  • [Publication-country] China
  •  go-up   go-down


31. Isik M, Dikbas O, Ozcakar L, Isik B, Altundag K: Dermatitis artefacta in a patient with recurrent larynx cancer: a rare self-inflicted dermatosis. South Med J; 2004 Oct;97(10):1024-5
MedlinePlus Health Information. consumer health - Skin Conditions.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Dermatitis artefacta in a patient with recurrent larynx cancer: a rare self-inflicted dermatosis.
  • [MeSH-major] Compulsive Personality Disorder / drug therapy. Life Style. Skin Diseases / etiology
  • [MeSH-minor] Anti-Anxiety Agents / therapeutic use. Carcinoma, Squamous Cell / surgery. Humans. Laryngeal Neoplasms / surgery. Male. Middle Aged. Neoplasm Recurrence, Local / surgery

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 15558942.001).
  • [ISSN] 0038-4348
  • [Journal-full-title] Southern medical journal
  • [ISO-abbreviation] South. Med. J.
  • [Language] eng
  • [Publication-type] Case Reports; Letter
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Anti-Anxiety Agents
  •  go-up   go-down






Advertisement